Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaboxadol. Lundbeck/Merck.

Richard Huckle1

  • 1Actelion Ltd, Innovation Center, Allschwil, Switzerland. richard.huckle@actelion.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 10, 2004
PubMed
Summary

Gaboxadol, a GABAA agonist, is being developed for sleep disorders. This potential treatment is currently in phase III clinical trials.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting.

Journal of neurodevelopmental disorders·2026
Same author

PBT-1 Prana Biotechnology.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Pregabalin (Pfizer).

Current opinion in investigational drugs (London, England : 2000)·2004
Same author

Lerisetron. FAES.

Current opinion in investigational drugs (London, England : 2000)·2003

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Sleep disorders represent a significant global health burden.
  • GABAA receptor modulation is a key target for sedative-hypnotic therapies.

Purpose of the Study:

  • To evaluate the efficacy and safety of gaboxadol for treating sleep disorders.
  • To advance gaboxadol through late-stage clinical development.

Main Methods:

  • Gaboxadol, a selective GABAA agonist, is undergoing rigorous phase III clinical trials.
  • Clinical trial design focuses on assessing sleep quality and duration parameters.

Main Results:

  • Results from phase III trials are pending.
  • Data will inform the potential therapeutic application of gaboxadol.

Conclusions:

  • Gaboxadol represents a promising therapeutic candidate for sleep disorders.
  • Further clinical data will determine its role in sleep medicine.